Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Tumour-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy tissues and can potentially be recognized as neo-antigens by the mature T-cell repertoire. Their systematic targeting by vaccine approaches, however, has been hampered by the fact that every patient's tumour possesses a unique set of mutations ('the mutanome') that must first be identified. Recently, we proposed a personalized immunotherapy approach to target the full spectrum of a patient's individual tumour-specific mutations. Here we show in three independent murine tumour models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that, unexpectedly, the majority of the immunogenic mutanome is recognized by CD4(+) T cells. Vaccination with such CD4(+) immunogenic mutations confers strong antitumour activity. Encouraged by these findings, we established a process by which mutations identified by exome sequencing could be selected as vaccine targets solely through bioinformatic prioritization on the basis of their expression levels and major histocompatibility complex (MHC) class II-binding capacity for rapid production as synthetic poly-neo-epitope messenger RNA vaccines. We show that vaccination with such polytope mRNA vaccines induces potent tumour control and complete rejection of established aggressively growing tumours in mice. Moreover, we demonstrate that CD4(+) T cell neo-epitope vaccination reshapes the tumour microenvironment and induces cytotoxic T lymphocyte responses against an independent immunodominant antigen in mice, indicating orchestration of antigen spread. Finally, we demonstrate an abundance of mutations predicted to bind to MHC class II in human cancers as well by employing the same predictive algorithm on corresponding human cancer types. Thus, the tailored immunotherapy approach introduced here may be regarded as a universally applicable blueprint for comprehensive exploitation of the substantial neo-epitope target repertoire of cancers, enabling the effective targeting of every patient's tumour with vaccines produced 'just in time'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, peptide-based immunotherapeutics often tend to induce primarily CD4+ T-cell responses [36].”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mutated epitopes of Pbk and Actn4 were recognized and reacted to by CD8+ or CD4+ T cells, respectively, upon RNA monotope vaccinations and showed good MHC class I binding scores (‘low score’ 0.1 and 0.2, respectively) (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Additional neoatigens formulated in the mRNA vaccine may help improve the anti-tumor response of mRNA vaccines using neoantigens, such as demonstrated by Kreiter et al. (25).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [25]
In the citing paper
“Interestingly, we also observed an elevated percentage of ChAT–GFP+ cells among CD4+ T cells carrying natural TCRs (TCR Vβ5–) (Fig. 4j,k), suggesting that ChAT expression in T cells can also be induced through ‘antigen spreading’35.”
From Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma (2023) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Cited by
Items 701–800 of 1,001
Xia, W., Feng, Z., Wang, Y., Lei, R., Zhou, Y., Zhuo, Y., Xie, R., Dong, H., Zhao, X., Guan, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c13320 · Cited by 19
Graciotti, M., Marino, F., Pak, H., Baumgaertner, P., Thierry, A., Chiffelle, J., Perez, M. A. S., Zoete, V., Harari, A., Bassani‐Sternberg, M., et al. (2020) · Vaccines · doi:10.3390/vaccines8020271 · Cited by 18
Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth
Das, M., Zhou, X., Liu, Y., Das, A., Vincent, B. G., Li, J., Liu, R., & Huang, L. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100856 · Cited by 18
Koşaloğlu‐Yalçın, Z., Blazeska, N., Carter, H. K., Nielsen, M., Cohen, E. E. W., Kufe, D. W., Conejo-Garcia, J. R., Robbins, P. F., Schoenberger, S. P., Peters, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.735609 · Cited by 21
Self-citationCommensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines
Tomasi, M., Dalsass, M., Beghini, F., Zanella, I., Caproni, E., Fantappiè, L., Gagliardi, A., Irene, C., König, E., Frattini, L. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9111356 · Cited by 21
Bekri, S., Rodney-Sandy, R., Gruenstein, D., Mei, A. H.-C., Bogen, B., Castle, J. C., Levey, D. L., & Cho, H. J. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003572 · Cited by 18
Self-citationA Highly Effective System for Predicting MHC-II Epitopes With Immunogenicity
Xu, S., Wang, X. H., & Fei, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888556 · Cited by 22
Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells
Liang, Y., Xu, Q., Liu, S., Li, J., Wang, F., Li, Z., Liao, L., Lu, Y., Li, Y., Mu, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.939940 · Cited by 18
“Minigene construction followed the previously described method (55).”
MethodSystemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
Escors, D., Bocanegra, A., Chocarro, L., Blanco, E., Piñeiro‐Hermida, S., Garnica, M., Fernández, L., Vera, R., Arasanz, H., & Kochan, G. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113241 · Cited by 19
Vormehr, M., Reinhard, K., Blatnik, R., Josef, K., Beck, J. D., Salomon, N., Suchan, M., Selmi, A., Vascotto, F., Zerweck, J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1553478 · Cited by 18
“RNAs were synthesized by BioNTech RNA Pharmaceuticals GmbH.12 Smc3 RNA encodes 27 amino acids with the mutated amino acid in the center (position 14).”
BackgroundMethodInfluentialSelf-citationMa, S., Chee, J., Fear, V. S., Forbes, C. A., Boon, L., Dick, I. M., Robinson, B. W. S., & Creaney, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1684714 · Cited by 20
“CD8 T cells typically respond to 8-11mer short peptide epitopes in an ELISPOT assay, whereas both CD4 and CD8 T cells can respond to 27mer long peptides in an ELISPOT assay with antigen-presenting cells.(32) To further explore responses to our neo-antigen candidates, we tested long peptides encoding the top nine expre…”
BackgroundThe Gut Microbiome Controls Liver Tumors via the Vagus NervePreprint
Bauer, K. C., Trehan, R., Ruf, B., Myojin, Y., Benmebarek, M.-R., Ma, C., Seifert, M., Nur, A., Qi, J., Huang, P., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576951 · Cited by 20
Cespiati, A., Cinque, F., Meroni, M., Lombardi, R., Dongiovanni, P., & Fracanzani, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11020586 · Cited by 18
“Indeed, HCC onset and spreading is physiologically prevented by intrahepatic CD4+ T lymphocytes by fostering apoptotic processes in the hepatocytes that harbor cancer mutations [87].”
BackgroundMonophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy
Li, R., Hao, Y., Pan, W., Wang, W. T., & Min, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.09.013 · Cited by 18
Zheng, W., Li, S., Shi, Z., Su, K., Ding, Y., Zhang, L., Tang, Q., Han, J., Zhao, H., Wang, F., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02837-2 · Cited by 18
“M30-FNs were prepared by fusing M30, a B16F10 melanoma neoan-tigen, to the N-terminus of optimized ferritin [7].”
MethodYu, Z., Tan, Z., Lee, B. K., Tang, J., Wu, X., Cheung, K., Lo, N. T. L., Man, K., Liu, L., & Chen, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5856 · Cited by 19
“However, previous studies have shown that high frequency of broadly reactive anti-tumor T cell responses may lead to the reduction of MDSCs [5, 14].”
BackgroundImmunotherapy for Lung Malignancies
Chee, J., Robinson, B. W. S., Holt, R. A., & Creaney, J. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.007 · Cited by 21
Next-Generation Sequencing to Guide Treatment of Advanced Melanoma
Griewank, K., & Schilling, B. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0260-6 · Cited by 17
Advances in Development of mRNA-Based Therapeutics
Huang, L., Zhang, L., Li, W., Li, S., Wen, J., Li, H., & Liu, Z. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_222 · Cited by 21
Swartz, A. M., Congdon, K. L., Nair, S. K., Li, Q.-J., Herndon, J. E., Suryadevara, C. M., Riccione, K. A., Archer, G. E., Norberg, P. K., Sanchez-Perez, L. A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-020-00273-5 · Cited by 18
Yu, J., Wang, Q., Zhang, X., Guo, Z., & Cui, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685377 · Cited by 20
“The screening methods used to identify tumor neoantigens currently mainly include target gene sequencing (3), exome sequencing (4, 5), antigen ligandomics and mass spectrometry combination technology (4, 6, 7), and tandem micro gene sequencing methods (8, 9)(as shown in Figure 1).”
MethodTargeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., López-Beltrán, A., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 19
PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
Choudhury, R., Symonds, P., Paston, S. J., Daniels, I., Cook, K., Gijon, M., Metheringham, R. L., Brentville, V. A., & Durrant, L. G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003526 · Cited by 17
Griffith, B. D., Turcotte, S., Lazarus, J., Lima, F., Bell, S., Delrosario, L., McGue, J. J., Krishnan, S., Oneka, M. D., Nathan, H., et al. (2022) · Cancers · doi:10.3390/cancers14174092 · Cited by 19
“Similarly, vaccines designed to be expressed by MHC-II molecules have been effective in mediating tumor clearance in some murine models of cancer [35].”
BackgroundValentini, D., Rao, M., Meng, Q., von Landenberg, A., Bartek, J. J., Sinclair, G., Paraschoudi, G., Jäger, E., Peredo, I. H., Dodoo, E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24955 · Cited by 17
“The existence of measurable and potentially durable immune responses directed against a distinct repertoire of private neoantigens in patients with advanced cancers has clinically relevant implications also for the development of personalized cancer vaccines [37].”
BackgroundDillman, R. O., Cornforth, A. N., McClay, E. F., & DePriest, C. B. (2019) · Melanoma Management · doi:10.2217/mmt-2018-0010 · Cited by 19
Advances in mRNA vaccine therapy for breast cancer research
Li, J., Jiang, R., Wang, J., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02542-y · Cited by 18
“Neoepitope-targeted immunotherapies are restricted in their efficacy due to the limited number of cancer-associated mutations that can trigger strong immune responses [80, 81].”
Wu, Y., Sun, G., Ren, W., Yang, G., Wang, C., Ye, X., Chen, Y., Pang, X., Zhang, Q., Wang, Z. J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03681-8 · Cited by 16
“In this study, one B16-M01 [49] and seven Hepa1-6 neoantigens (9-mer mutant) [50] were selected to prepare mRNA vaccinations (Table S2).”
Personalized Cancer Vaccines: Current Advances and Emerging Horizons
Lu, L., Lu, X., & Luo, W. (2025) · Vaccines · doi:10.3390/vaccines13121231 · Cited by 18
“In early preclinical work, Kreiter et al. reported that fewer than 10% of 184 predicted neoantigens derived from three murine tumor lines induced detectable CD8 + T cell responses, suggesting the high false-positive rate inherent to prediction pipelines [41].”
Strategies for Testing Intervention Matching Schemes in Cancer
Schork, N. J., Goetz, L. H., Lowey, J., & Trent, J. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1947 · Cited by 16
“, modified T-cells – are the same, the actual individual replacement cells made are unique by making them ‘match’ the patient’s tumor neo-antigen profile.[5] The cells made are also unique given that they came from an individual patient, unlike ‘allogenic’ Tcell therapy where cells derived from one patient are infused…”
BackgroundFueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity
Hernandez, R., & Malek, T. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878377 · Cited by 18
“SNV neoantigen vaccination also led to induction of CTL responses against the well-characterized immunodominant AH1 antigen of the CT26 colon carcinoma, indicative of antigen spreading (38, 39).”
BackgroundAntigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy
Chen, X., Cheng, K., Wang, X., Liu, J., Liang, J., Liu, G., Lu, Y., Tang, M., Qian, D., Chen, L., et al. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101922 · Cited by 16
Zheng, P., He, J., Yang, Z., Fu, Y., Yang, Y., Li, W., Ding, Y., Yang, X., & Ma, Y. (2023) · Small · doi:10.1002/smll.202302922 · Cited by 17
Yang, X., Jiang, S., Liu, F., Li, Z., Liu, W., Zhang, X., Nan, F., Li, J., Yu, M., Wang, Y., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03937-8 · Cited by 16
Role of T Lymphocytes in Glioma Immune Microenvironment: Two Sides of a Coin
Noor, L., Upadhyay, A., & Joshi, V. (2024) · Biology · doi:10.3390/biology13100846 · Cited by 16
“Additionally, in three mouse tumor models, CD4 + T cells identified the immunogenic mutanome of non-synonymous cancer mutations more often than CD8 + T cells [79].”
BackgroundYe, Z., Li, Z., Jin, H., & Qian, Q. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_3 · Cited by 19
Verdegaal, E. M. E., & van der Burg, S. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01113 · Cited by 16
Role of tumor gene mutations in treatment response to immune checkpoint blockades
Wang, M., Liu, Y., Wei, X., & Wei, Y. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz006 · Cited by 16
“To achieve an adequate and durable T cell response, multiple vaccinations and incorporation of MHC class II peptides are required.(129,130) Study on these subjects will undoubtedly provide new perspectives for improvement of the ICB treatment response.”
Background“Cytokine-microfactories” recruit DCs and deliver tumor antigens via gap junctions for immunotherapy
Guo, L., Wei, R., Sun, R., Yang, Q., Li, G.-J., Wang, L.-Y., Luo, H., & Feng, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.040 · Cited by 16
Fan, X., Song, J., Fan, Y., Li, J., Chen, Y., Zhu, H., & Zhang, Z. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s338284 · Cited by 19
“scavenging tumor cells as cytotoxic T cells in two studies.(48,49) B cells were humoral immune cells, which”
BackgroundCRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 18
Jurj, A. M., Paşca, S., Braicu, C., Rusu, I., Korban, S. S., & Berindan‐Neagoe, I. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.002 · Cited by 17
Lee, H. H., Hong, S. H., Rhee, J. H., & Lee, S. E. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2798 · Cited by 17
“Cancer vaccines are administered to humans in cell-, viral vector-, nucleic acid- or peptide-based forms (3,12-16).”
BackgroundMembrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system
Jin, Y., Deng, Z., & Zhu, T. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02805-6 · Cited by 17
“In addition, among the immunogenic neoantigen epitopes screened from three different mouse models of melanoma, colon cancer and breast cancer, 80–90% of immunogenic neoantigen epitopes screened in mouse models of some cancers were recognized by CD4+T cells rather than CD8+T cells, suggesting that tumor-specific neoant…”
BackgroundTumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display
Tveita, A. A., Fauskanger, M., Bogen, B., & Haabeth, O. A. W. (2016) · Oncotarget · doi:10.18632/oncotarget.11946 · Cited by 17
“High-throughput bioinformatics surveys in various tumor models identify a large number of immunogenic MHC class II neoepitopes, and vaccination with such neoepitopes can elicit protective immune responses including epitope spreading [7].”
BackgroundCurrent Strategies to Enhance Anti-Tumour Immunity
Cook, K., Durrant, L. G., & Brentville, V. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020037 · Cited by 21
Nanomaterials for oncotherapies targeting the hallmarks of cancer
Dai, X., Yu, L., Zhao, X., & Ostrikov, K. (2020) · Nanotechnology · doi:10.1088/1361-6528/ab99f1 · Cited by 16
Kvistborg, P., Clynes, R., Song, W., & Yuan, J. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0126-0 · Cited by 17
Targeting the cancer mutanome of breast cancer
Radvanyi, L. G. (2018) · Nature Medicine · doi:10.1038/s41591-018-0065-z · Cited by 16
A universal MHCII technology platform to characterize antigen-specific CD4+ T cells
Vyasamneni, R., Kohler, V. L., Karki, B., Mahimkar, G., Esaulova, E., McGee, J., Kallin, D., Sheen, J. H., Harjanto, D., Kirsch, M., et al. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100388 · Cited by 16
Quantifying immune-based counterselection of somatic mutations
Yang, F., Kim, D., Nakagawa, H., Hayashi, S., Imoto, S., Stein, L. D., & Roth, F. P. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008227 · Cited by 18
Stem Cells as Therapeutic Targets in Colorectal Cancer
Zalewski, A., Snook, A. E., & Waldman, S. A. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0099 · Cited by 15
Yuan, J., Yuan, X., Wu, K., Gao, J., & Li, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658254 · Cited by 19
“To determine whether neoantigen-specific T cells were activated by this local treatment, we examined the neoantigen-specific immune response based on previous neoepitope-related studies in these two tumor models by next-generation sequencing (28).”
BackgroundMethodRNA Engineering for Public Health: Innovations in RNA-Based Diagnostics and Therapeutics
Thavarajah, W., Hertz, L. M., Bushhouse, D. Z., Archuleta, C. M., & Lucks, J. B. (2021) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-101420-014055 · Cited by 19
D’Alise, A. M., Leoni, G., Lucia, M. D., Langone, F., Nocchi, L., Tucci, F. G., Micarelli, E., Cotugno, G., Troise, F., Garzia, I., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003480 · Cited by 15
“Several preclinical studies have already shown that cancer vaccines targeting tumor nAgs can be effective in a variety of murine tumor models, 10 11 supporting the initiation of several clinical studies.”
What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination
Redwood, A., Dick, I. M., Creaney, J., & Robinson, B. W. S. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2038403 · Cited by 19
“In contrast, as many as 40–60% of predicted neoantigens can stimulate de novo T-cell responses after vaccination.(7,8,10,11,60,87) These latter, novel, antigens should not have been subjected to preexisting immunosup-”
BackgroundLee, S., Lee, C. M., Won, J. E., Jang, G.-Y., Lee, J. H., Park, S. H., Kang, T. H., Han, H. D., & Park, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121677 · Cited by 15
Immunotherapies targeting neoantigens are effective in PD ‐1 blockade‐resistant tumors
Sun, C., Nagaoka, K., Kobayashi, Y., Maejima, K., Nakagawa, H., Nakajima, J., & Kakimi, K. (2022) · International Journal of Cancer · doi:10.1002/ijc.34382 · Cited by 17
“Tumor mutation-associated neoantigens, selectively expressed on tumors, can elicit T-cell-mediated immune responses.(13,14) In addition, early clinical investigations provided evidence supporting the relevance of neoantigen vaccination to clinical benefits.”
BackgroundImmune engineering: From systems immunology to engineering immunity
Jiang, N. J. (2017) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2017.03.002 · Cited by 15
Platten, M., Bunse, L., Riehl, D., Bunse, T., Ochs, K., & Wick, W. (2018) · Current Treatment Options in Neurology · doi:10.1007/s11940-018-0498-1 · Cited by 15
Riccione, K. A., He, L.-Z., Fecci, P. E., Norberg, P. K., Suryadevara, C. M., Swartz, A. M., Healy, P. N., Reap, E. A., Keler, T., Li, Q.-J., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502904 · Cited by 16
Reimann, H., Nguyen, A., Sanborn, Z., Vaske, C. J., Benz, S. C., Niazi, K. R., Rabizadeh, S., Spilman, P., Mackensen, A., Ruebner, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002605 · Cited by 18
“This is of particular interest as evidence has arisen that CD4+ T cells alone can actually drive therapeutic immune responses to cancer, 35 36 including neoantigen recognition by CD4+ T cells as reported by Linnemann et al .”
Levin, N., Pato, A., Cafri, G., Eisenberg, G., Peretz, T., Margalit, A., Lotem, M., & Gross, G. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000150 · Cited by 15
Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14567 · Cited by 16
Self-citationKeivany, M. R., Asrami, E. S., Besharatloo, M., Latifi, H., & Barjasteh, A. H. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04177-7 · Cited by 18
“In CRC, dMMR– MSI-H tumors exhibit mutation burdens nearly 20 times higher than pMMR–MSI-L counterparts, fostering neo-epitope generation capable of eliciting robust CD8 ⁺ T-cell responses and cytolytic activity [205–207].”
Historical perspective and future directions: computational science in immuno-oncology
Ricker, C. A., Meli, K., & Allen, E. M. V. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008306 · Cited by 15
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
Garzia, I., Nocchi, L., Avalle, L., Troise, F., Leoni, G., Seclì, L., Antonucci, L., Cotugno, G., Allocca, S., Romano, G., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0609 · Cited by 14
“Cells were used on passage 7 – 9 after being tested for the absence of Mycoplasma contamination by PCR. Cells on passage 8 were sequenced by next-generation sequencing (NGS) to assess the presence of mutations previously described (12, 19).”
Rojas, J. J., Hoecke, L. V., Conesa, M., Bueno-Merino, C., del Canizo, A., Riederer, S., Barcia, M., Brosinski, K., Lehmann, M. H., Volz, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.014 · Cited by 15
Large-scale transcript variants dictate neoepitopes for cancer immunotherapy
Ji, S., Wang, F., Wu, Y., Hu, H., Xing, Z., Zhu, J., Xu, S., Han, T., Liu, G., Wu, Z., et al. (2025) · Science Advances · doi:10.1126/sciadv.ado5600 · Cited by 16
Therapeutic mRNA vaccine applications in oncology
Elliott, L. A., Foster, T. P., Castillo, P., Méndez-Gómez, H., & Sayour, E. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.044 · Cited by 17
Membrane-IL12 adjuvant mRNA vaccine polarizes pre-effector T cells for optimized tumor control
Peng, K., Zhao, X., Li, H., Fu, Y., & Liang, Y. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241454 · Cited by 14
Immunomodulatory effects of photothermal therapy in breast cancer: advances and challenges
Chen, L., Zhang, H., Hou, Y., Yunlong, W., & Feng, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544693 · Cited by 17
Gao, J., Yuan, X., Yuan, J., & Li, L. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02919-2 · Cited by 14
“To analyze whether the responsive T cells contained neoantigen-specific T cells, we synthesized twelve mutant neoantigen epitopes identified in previous study [23] (Supplementary Table 1) and screened them based on the mixed lymphocyte reaction intensity (Supplementary Figure S6d).”
Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis
Khan, I., MarElia, C. B., Lefler, J. E., Zuberi, M., Denbaum, E., Koide, A., Connor, D. M., Broome, A., Pécot, T., Timmers, C. D., et al. (2021) · Small GTPases · doi:10.1080/21541248.2021.1906621 · Cited by 15
Jeong, M., Kim, H., Yoon, J., Kim, D., & Park, J. (2022) · JCI Insight · doi:10.1172/jci.insight.146608 · Cited by 14
“When the splenocytes, isolated from mice, were incubated with gp70423-431, an immunodominant peptide expressed by 4T1 cells (36), the mcMEDI group exhibited significantly higher IFN-γ production compared with that in the other groups (Figure 4B).”
BackgroundHos, B. J., Tondini, E., Camps, M. G. M., Rademaker, W., van den Bulk, J., Ruano, D., Janssen, G. M. C., de Ru, A. H., van den Elsen, P. J., de Miranda, N. F. C. C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111485 · Cited by 15
Red Blood Cells-Based Vaccines for Ameliorating Cancer Chemoimmunotherapy
Su, L., Hao, Y., Li, R., Pan, W., Ma, X., Weng, J., & Min, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.001 · Cited by 14
Wang, J., Weiß, T., Neidert, M. C., Toussaint, N. C., Naghavian, R., Moreno, C. S., Foege, M., Ojer, P. T., Medici, G., Jelčić, I., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1741 · Cited by 14
Self-citationPANDORA v2.0: Benchmarking peptide-MHC II models and software improvements
Parizi, F. M., Marzella, D. F., Ramakrishnan, G., ‘t Hoen, P. A. C., Karimi-Jafari, M. H., & Xue, L. C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285899 · Cited by 14
Tsuruta, M., Ueda, S., Yew, P. Y., Fukuda, I., Yoshimura, S., Kishi, H., Hamana, H., Hirayama, M., Yatsuda, J., Irie, A., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1415687 · Cited by 14
Novel tumour antigens and the development of optimal vaccine design
Brentville, V. A., Atabani, S., Cook, K., & Durrant, L. G. (2018) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135518768769 · Cited by 17
Ji, M., Zhu, J., Xie, X.-X., Liu, D., Wang, B., Yu, Z., & Liu, R. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102223 · Cited by 15
T cell receptor therapy against melanoma—Immunotherapy for the future?
Winge-Main, A., Wälchli, S., & Inderberg, E. M. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12927 · Cited by 15
“Several reports have shown that neoantigens stimulate predominantly CD4 T cells versus CD8 T cells (95, 96).”
BackgroundGraph-theoretical formulation of the generalized epitope-based vaccine design problem
Dorigatti, E., & Schubert, B. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008237 · Cited by 14
Mohammadi, M., Dehghani, P., Mohseninia, A., Roozbehani, M., Hemphill, A. F., & Hesamizadeh, K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29946 · Cited by 14
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
Bendjama, K., & Quéméneur, É. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1334746 · Cited by 14
“Recent developments of advanced formulations targeting RNA to the spleen, and compatible with repeated administrations, have renewed the interest in RNA vaccines and opened up opportunities to target neoantigens using these approaches.(33)”
BackgroundZhang, X., Goedegebuure, S. P., Myers, N. B., Vickery, T. L., McLellan, M. D., Gao, F., Sturmoski, M., Chen, M. Y., Kim, S. W., Chen, I., et al. (2021) · medRxiv · doi:10.1101/2021.11.19.21266466 · Cited by 16
“A potential shortcoming of pVACtools as used in this trial is the emphasis on MHC class I binding given the importance of CD4 cells in reprogramming the tumor microenvironment and promoting antitumor immunity [61].”
MethodShen, Y., Yu, L., Xu, X., Yu, S., & Yu, Z. (2022) · Cancer Innovation · doi:10.1002/cai2.26 · Cited by 13
“…amino acid residue flanked on their N ‐ and C ‐ termini by 12 – 13 amino acids were synthesized and used to transfect APCs; these TMGs have resulted in the identification of neoantigens in melanoma, colorectal carcinoma, and cholangiocarcinoma patients and mouse tumor models [14, 36, 51, 52].”
BackgroundNakajima, S., Kaneta, A., Okayama, H., Saito, K., Kikuchi, T., Endo, E., Matsumoto, T., Fukai, S., Sakuma, M., Sato, T., et al. (2023) · Cancers · doi:10.3390/cancers15102826 · Cited by 13
“Further investigation is needed to understand the role of tumor-cell intrinsic cGAS-STING, not only in the activation of immune cells in the TME but also in tumor cell proliferation in CRC.”
BackgroundInfluentialWolf, S. P., Anastasopoulou, V., Drousch, K., Diehl, M. I., Engels, B., Yew, P. Y., Kiyotani, K., Nakamura, Y., Schreiber, K., Schreiber, H. W., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2905 · Cited by 13
Kim, S. H., Lee, B. R., Kim, S., Kim, S., Kim, M.-S., Kim, J., Lee, I., Kim, H.-S., Nam, G., Kim, I., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01259-2 · Cited by 14
“4e).”
Wang, B., Peng, X.-B., Li, J., Wang, Y.-R., Chen, L.-P., Wu, M.-H., Zhang, Y.-Y., Wang, W., Feng, D., Tang, S.-H., et al. (2024) · American Journal of Cancer Research · doi:10.62347/nvfb3780 · Cited by 14
Ahmed, S., Mazhar, M. S., & Shabbir, M. F. (2024) · Targeted Cancer Therapy Connect · doi:10.69709/ciconnect.2024.194763 · Cited by 18
Individualized Neoantigen-Directed Melanoma Therapy
Khaddour, K., & Buchbinder, E. I. (2025) · American Journal of Clinical Dermatology · doi:10.1007/s40257-025-00920-4 · Cited by 15
Fu, X., Tao, L., Wu, W., & Zhang, X. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.09.002 · Cited by 13
“Taken together, these data demonstrate that tumor destruction by FusOn-PL can induce polyneo-epitope T cells against predominately MHC class II neoantigens, which is in agreement with the report by Kreiter et al.(36) for similar findings in both B16 and CT26 tumor models.”
BackgroundMethodResultInfluentialThe Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
Arnaud, M., Bobisse, S., Chiffelle, J., & Harari, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.701636 · Cited by 14
“In addition, CD4 T cell’s help is essential to generate efficient tumor-reactive effector CD8 T cells (65), notably during the process of epitope spreading (29, 66).”
BackgroundSymonds, P., Marcu, A., Cook, K., Metheringham, R. L., Durrant, L. G., & Brentville, V. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.764462 · Cited by 14
“immune phenotypes shown among the selected eluted peptides in this study supports the hypothesis that tumour presented MHCII epitopes can be specific for both regulatory and proinflammatory responses, a phenomenon also seen by others (8, 10, 40).”
ResultZhu, L., Zhang, X., Xu, S., Hu, M., Zhao, Z., Zhao, G., Xiao, Z., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1111246 · Cited by 15
“02 immunogenic, and most immunogenic mutations could be recognized by CD4+ T lymphocytes (17).”
BackgroundLiu, Y., Li, S., Chen, L., Lin, L., Xu, C., Qiu, H., Li, X., Cao, H., & Liu, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341596 · Cited by 15
Li, J., Feng, J., Li, Z., Ni, Y., Liu, L., Xia, L., Chai, Z., Zhuang, N., Xu, J., He, Y., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00625-7 · Cited by 16
Metadata
- Authors
- Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., Tadmor, A. D., Schoenberger, S. P., Huber, C., Türeci, Ö., & Sahin, U.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- La Jolla Institute for Immunology (US)
- ORCID
- Venue
- Nature
- Published
- 2015-04-22
- Volume
- 520
- Issue
- 7549
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4838069
- OpenAlex
- W2079696222
- Cited by
- 1,243
- References
- 31
- Citations by year
- 2026: 64 · 2025: 93 · 2024: 114 · 2023: 120 · 2022: 124 · 2021: 149 · 2020: 144 · 2019: 101 · 2018: 99 · 2017: 99 · 2016: 95 · 2015: 38
- FWCI
- 54.27
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-06-03)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (R01AI107010)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- tumour mutations, MHC class II epitopes, neoantigens, CD4+ T cells, mRNA vaccines, personalized cancer immunotherapy, MHC class II binding prediction, tumor microenvironment, cytotoxic T lymphocytes, tumor rejection, exome sequencing, tumor immunogenicity
- MeSH terms
- Algorithms, Animals, Histocompatibility Antigens Class II, Computer Simulation, Disease Models, Animal, Female, Humans, Immunotherapy, Melanoma, Experimental, Mutation, CD4-Positive T-Lymphocytes, Survival Analysis, Sequence Analysis, DNA, Epitopes, T-Lymphocyte, Cancer Vaccines, Mice, Precision Medicine, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.